Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.

MedPacto, an innovative drug development company, announced on September 1 that it will begin a Phase 2 clinical trial of its new drug candidate "Vactosertib" for osteosarcoma patients. MedPacto is ...

Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers. Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in ...

MedPacto, an innovative new drug development company, announced on October 17 that it will present interim results from its Phase 1 clinical trial of the immuno-oncology candidate "Vactosertib" for ...

Dr. Alex Huang, professor of pediatrics at Case Western Reserve University School of Medicine, whose immunotherapy research has been supported by Pediatric Cancer Research Foundation grants, is set to ...